See press release:

http://www.aegis.com/news/pr/2003/PR030411.html

Stampidine First Effective Agent Against FIV: Offers Hope to AIDS Patients
PRNewswire - April 4, 2003

ROSEVILLE, Minn., April 4 /PRNewswire/ -- Scientists from Parker Hughes
Cancer Center report in the April issue of Antimicrobial Agents and
Chemotherapy, the official journal of the American Society for Microbiology,
that stampidine is the first single agent to be safe and effective in
treating cats chronically infected with feline immunodeficiency virus, or
FIV. That's significant because FIV in cats is similar to HIV in humans. It
is hoped that advances in the treatment of FIV can be translated to the
treatment of HIV.
During the study cats treated with stampidine had their viral FIV loads
reduced. At higher doses stampidine eliminated FIV in cats with no side
effects. Current anti-AIDS drugs AZT and 3CT are not effective alone in
treating FIV. "We are cautiously optimistic that stampidine will prove to be
more effective against HIV than currently available drugs because it is
proving to be more effective than current drugs in the feline model," said
Dr. Fatih Uckun, M.D., Ph.D., Medical Director of Parker Hughes Cancer
Center.
"There is still much work that needs to be done but if these results can be
translated to the treatment of AIDS it will offer renewed hope to AIDS
patients who are resistant to currently available drugs," Uckun added.
Parker Hughes scientists are encouraged by earlier studies that show
stampidine to be 100 to 1000 times more effective against HIV than it is
against FIV.
Reference: Antimicrob Agents Chemother 2003 Apr;47(4):1233-40. In vivo
antiretroviral activity of stampidine in chronically feline immunodeficiency
virus infected cats. Uckun FM, Chen CL, Samuel P, Pedergrass S,
Venkatachalam TK, Waurzyniak B, Qazi S.
SOURCE Parker Hughes Cancer Center
Web Site: http://www.parkerhughes.org

(sorry to tack on to my on post.)